Earnings call transcripts

Management framed the quarter as a liquidity and deposit-franchise stress test that reinforced a more conservative balance-sheet and capital plan.

Management framed recovery as a gradual, U-shaped process, with profits not expected to recover notably until 2024. 82% of Q1 new unsecured loans were in the top three credit tiers, versus 41% a year earlier.

Management framed growth as increasingly constrained by supply, while stressing sustained GLP-1 demand and investment to expand capacity.

Management framed the quarter as broad-based ICL share gains despite weak refractive markets, with China recovered and U.S. launch investments still building adoption.

Management framed 2023 as a transition toward scale and profitability, with cost cuts, product launches and channel normalization underpinning second-half confidence.

Management framed recovery as U-shaped but contingent on SMB conditions and credit-enhancement negotiations, prioritizing asset quality and margin sustainability over near-term growth.

Management framed 2023 around strong GLP-1 demand and capacity expansion, while stressing supply limits and unusually high uncertainty around market growth.

Management framed 2023 as an investment year, with confidence in China’s recovery and a sharper push to build U.S. EVO adoption. $5 million of Q4 sales were removed amid China’s COVID-related disruption.

Management framed 2023 around maintaining earnings while repositioning the balance sheet and defining growth beyond the $10 billion Durbin limit.

Management framed 2022 as strong share-gain execution but reset costs and profitability timing after weaker European demand and channel caution.

Management framed performance as broad-based, with GLP-1 demand driving growth while supply constraints and declining insulin sales shaped the outlook. 40% of U.S.

Management framed the reset as temporary China demand deferral and currency pressure, while shifting resources toward EVO and signaling stronger U.S. momentum.